Parinda A. Mehta, MD
- Member, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- parinda.mehta@cchmc.org
- Board Certified
About
BA: Graduated from Parle College, Mumbai, India, 1988.
MD: G.S. Medical College and K.E.M Hospital, Mumbai, India, 1993.
Residency: Upstate Medical University (UMU) - State University of New York (SUNY), Syracuse, NY, 2002.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2005.
Certification: Board Certification, Pediatrics, 2002; Board Certification, Pediatric Hematology Oncology, License, State of Ohio.
Services and Specialties
Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Fanconi Anemia, Leukemia
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. Biology of Blood and Marrow Transplantation. 2019; 25:2416-2421.
Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation. 2018; 24:e11-e19.
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer. 2018; 65:e27034.
Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Journal of Antimicrobial Chemotherapy. 2018; 73:1651-1658.
T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. Bone Marrow Transplantation. 2024; 59:23-33.
Gonadal function in pediatric Fanconi anemia patients treated with hematopoietic stem cell transplant. Haematologica: the hematology journal. 2023; 108:2358-2368.
Phenotypes of adults with Fanconi anaemia. British Journal of Haematology. 2023; 201:133-139.
356 Children Under 2 Years Old Treated with Ruxolitinib for Acute and Chronic Graft-Versus-Host-Disease Demonstrate Variable Pharmacokinetics. Transplantation and cellular therapy. 2023; 29:s271-s272.
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and cellular therapy. 2022; 28:681-693.
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplantation and cellular therapy. 2022; 28:696.e1-696.e7.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey